On account of increasing number of cases related to high blood pressure and diabetes, growth in pipeline of peripheral arterial disease is anticipated in the next few years. One of the main causes of peripheral arterial disease is smoking, which leads to the building up of plaque inside the arteries that carry oxygen rich blood. As per the data provided by World Health Organization in 2015, nearly 1.1 billion people were addicted to smoking. Moreover, increasing number of people are being diagnosed with high blood pressure, diabetes and other lifestyle related diseases on account of unhealthy dietary habits, growing pressure at work, etc. On the back of these factors, growth in pipeline of peripheral arterial disease therapeutics is anticipated over next few years.
In October 2015, CorVascular Diagnostics, LLC entered into a collaboration and distribution agreement with Vasamed Inc., for the development of diagnostics through SensiLase PAD-IQ technology. Vasamed Inc. provided the dependable, reproducible measurement of tissue perfusion of the extremities particularly in patients having combined peripheral arterial disease and diabetes. In June 2016, Highmark Health, Allegheny Health Network and Avinger, Inc., entered into a collaboration to evaluate Pantheris, Avinger’s novel image-guided atherectomy device for the treatment of peripheral arterial disease (PAD). The partnership was a part of Highmark Health’s VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovation Program. In February 2017, Profusa Inc. and North Carolina State University’s ASSIST Center entered into collaboration for developing an ultrathin flexible-patch reader worn on the skin for continuous wireless monitoring of tissue oxygen in patients undergoing treatment for peripheral arterial disease (PAD), which has been awarded a $1.5 million in Phase II Small Business Innovation Research (SBIR) grant, administered by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). In November 2016, Reliq Health Technologies Inc. signed an agreement with Hamilton Health Sciences and McMaster University in Hamilton for the improvement of health outcomes for patients with peripheral arterial disease.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/peripheral-arterial-disease-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of peripheral arterial disease therapeutics include Bayer AG, Juventas Therapeutics, Inc., Proteon Therapeutics, Inc., Humacyte, Inc., Veryan Medical Ltd., SurModics, Inc., Acotec Scientific Co., Ltd, Spectranetics Corporation, Cardionovum GmbH.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)